# InnoCare Pharma - Corporate & Scientific News Milestone Feed

> 🌐 **Language**: English | 中文版本: [诺诚健华新闻动态](https://www.innocarepharma.com/api/llms/news.txt)
>
> Official press releases, clinical trial disclosures, and regulatory milestones.

- **[2026-10-13] InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed / Refractory MZL in China**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en020261013-Approval-of-Phase-III-Clinical-Trial-of-Mesutoclax-with-Orelabrutinib-for-MZL)

- **[2026-10-12] InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en020261012-IND-Approval-of-Bispecific-Antibody-ICP-B161-Targeting-TL1A-and-IL-23p19)

- **[2026-09-28] Fierce Biotech：Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en120260928)

- **[2026-09-26] SCMP：China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en020260926-biotech-firms-value-chain-drug-deals-licensing)

- **[2026-09-24] InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en020260924-InnoCare-Announces-Collaboration-with-Lilly)

- **[2026-09-24] Shanghai Daily：InnoCare enters collaboration and license agreement with Lilly**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en120260924)

- **[2026-09-24] Reuters : China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en0202609241)

- **[2026-09-23] China Daily : InnoCare Pharma partners with Eli Lilly in drug research deal**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en1202609241)

- **[2026-09-09] InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en020260909-IND-Approval-of-Bispecific-AD-ICP-B381)

- **[2026-09-03] China Daily：InnoCare Pharma returns to profit on strong drug sales**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en120260904)

- **[2026-08-24] InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en020260824-InnoCare-2026-Interim-Results)

- **[2026-08-18] InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment Naive AML in China**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en020260818-Approval-of-Phase-III-Clinical-Trial-of-Mesutoclax-for-AML)

- **[2026-08-17] InnoCare 2026 Interim Results Earnings Call**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en020260817-InnoCare-2026-Interim-Results-Earnings-Call)

- **[2026-08-04] InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en020260804-Orelabrutinib-in-Combination-with-Mesutoclax-Granted-BTD-for-MZL)

- **[2026-07-27] InnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en020260727-TYK2i-Fadeucravacitinib-Meets-Primary-Endpoint-in-Phase-III-Psoriasis Study)

- **[2026-07-26] Fierce Biotech：InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en120260727)

- **[2026-07-16] InnoCare Announces Phase II Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Vitiligo**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en020260716)

- **[2026-07-15] Fierce Biotech：Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en120260716)

- **[2026-07-15] InnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Atomic Dermatitis**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en020260715)

- **[2026-07-13] InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL**
  *URL*: [View Article](https://www.innocarepharma.com/en/news/activity/en020260713-Publication-in-STTT-of-Phase-3-Results-Showing-Orelabrutinib-Significantly-Prolonged-PFS-in-1L-CLL-SLL)